Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB161734 drug interaction study with itraconazole, rifampin, and acid-reducing agents
NCT07018635Phase 1Completed
- Sponsor
- Incyte
- Start
- Jul 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of INCB161734 (4 cohorts), sponsored by Incyte. Primary endpoints: Maximum Plasma Concentration at 2 months, Area Under the Curve from Time Zero to Last Measurable Concentration at 2 months and 1 more. Started Jul 2025; status: completed.
02
Drugs
INCB161734
Beyond the preview
Go deeper on NCT07018635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018635.